Tirzepatide cardiovascular effects: unprecedented metabolic improvements but dedicated CV outcome trials needed | Research

The takeaway

Tirzepatide achieves unprecedented improvements in HbA1c, weight, blood pressure, and lipids with confirmed CV safety, but whether its dual GIP/GLP-1 mechanism provides cardiovascular benefits like GLP-1RAs remains uncertain pending ongoing large outcome trials.

Safe but benefit unproven
Tirzepatide achieves unprecedented metabolic improvements with confirmed cardiovascular safety, but whether it reduces CV events like semaglutide remains to be proven in ongoing trials

What the researchers found

Unprecedented: HbA1c, weight, BP, lipid improvements vs placebo and GLP-1RAs. CV safety confirmed. CV benefit: unknown (pending SURPASS-CVOT and other trials). GIP receptor CV contribution: not established.

Why it matters

Tirzepatide is being prescribed to millions but lacks the CV outcome data that made semaglutide a first-line cardiovascular drug. Understanding this evidence gap is critical for prescribing decisions.

How the study worked

Narrative review of tirzepatide cardiovascular trial data and ongoing outcome studies.

What this study cannot tell us

Review of available data with major outcome trials still ongoing. Cannot answer the key CV benefit question yet.

How to read the evidence

Review of phase 3 data. CV safety confirmed but CV benefit evidence pending dedicated outcome trials.

When this study was published

Published in 2025.

The bigger picture

Tirzepatide represents the most metabolically effective diabetes/obesity drug ever developed, but its cardiovascular story is incomplete. The ongoing outcome trials will determine whether it joins or surpasses semaglutide as a cardiovascular protective agent.

Questions still open

Will SURPASS-CVOT show CV benefit for tirzepatide?
Does GIP receptor activation help or hinder cardiovascular protection?
Should tirzepatide be used for CV protection before outcome trial results?

Common questions

Is tirzepatide good for the heart?

It is safe for the heart (confirmed in trials) and dramatically improves risk factors like weight, blood pressure, and cholesterol. However, unlike semaglutide, it has not yet been proven to actually reduce heart attacks and strokes in large outcome trials—those results are expected from ongoing studies.

Should I choose tirzepatide or semaglutide for heart protection?

Currently, semaglutide has stronger evidence for directly reducing cardiovascular events. Tirzepatide is metabolically more potent (more weight loss, better glucose control) but its cardiovascular event reduction is not yet proven. Once ongoing trials report, this comparison will be clearer.

Read the original research

Cardiovascular effects of tirzepatide.

The Journal of endocrinology, 264(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Sumithran, Priya; Russell, Anthony W; Zoungas, Sophia. (2025). Cardiovascular effects of tirzepatide.. The Journal of endocrinology, 264(2). https://doi.org/10.1530/JOE-24-0259